BEBT-109
BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research[1].
Product Specifications
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bebt-109.html
Concentration
10mM
Purity
98.72
Solubility
DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
C=CC(NC1=CC(NC2=NC=CC(N3C=CC4=NC(OC)=CC=C43)=N2)=C(OC)C=C1N(CCN(C)C)C)=O
Molecular Formula
C27H32N8O3
Molecular Weight
516.59
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-W423595/BEBT-109-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-W423595/BEBT-109-SDS-MedChemExpress.pdf
Scientific Category
Reference compound1
Clinical Information
Phase 2
CAS Number
[2050906-40-4]
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
